What changed in Alnylam Pharmaceuticals, Inc.'s latest annual report
In the year ended 31 Dec 2025, Alnylam Pharmaceuticals, Inc.'s revenue rose 65.2% to USD 3.71bn, from USD 2.25bn; shareholders' equity rose 1076.3% to USD 789.18m, from USD 67.09m; cash and cash equivalents rose 71.5% to USD 1.66bn, from USD 966.43m.
Year ended 31 Dec 2025. Source: 10-K filed 12 Feb 2026, read it on SEC EDGAR.
USD 2.25bn to USD 3.71bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 2.25bn | 3.71bn | Up 65.2% |
| Net income | -278.16m | 313.75m | Not comparable |
| Total assets | 4.24bn | 4.97bn | Up 17.1% |
| Total liabilities | 4.17bn | 4.18bn | Up 0.1% |
| Cash and cash equivalents | 966.43m | 1.66bn | Up 71.5% |
| Shareholders' equity | 67.09m | 789.18m | Up 1076.3% |
Questions people ask
Did Alnylam Pharmaceuticals, Inc.'s revenue grow last year?
Revenue grew 65.2%, from USD 2.25bn to USD 3.71bn in the year ended 31 Dec 2025.
Is Alnylam Pharmaceuticals, Inc. profitable?
Yes. Net income was USD 313.75m in the year ended 31 Dec 2025. The year before: a net loss of USD 278.16m.
How much cash and debt does Alnylam Pharmaceuticals, Inc. have?
At its latest year end (31 Dec 2025), Alnylam Pharmaceuticals, Inc. reported cash and cash equivalents of USD 1.66bn.
Where do these numbers come from?
From Alnylam Pharmaceuticals, Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Alnylam Pharmaceuticals, Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Pharmaceutical Preparations companies
- Eli Lilly And CompanyCash and cash equivalents up 122.4%
- Johnson & JohnsonNet income up 90.6%
- AbbVie Inc.Revenue up 8.6%
- Merck & Co., Inc.Long-term debt up 35.7%
- Abbott LaboratoriesNet income down 51.3%
- Pfizer IncCash and cash equivalents up 9.5%
- Vertex Pharmaceuticals Inc / MaTotal liabilities up 13.9%
- Bristol-Myers Squibb CompanyShareholders' equity up 13.1%